The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy and safety of pazopanib as a subsequent treatment after failure of other targeted agents in patients with metastatic renal cell carcinoma (mRCC).
Jiahuai Tan
No relevant relationships to disclose
Lance K. Heilbrun
No relevant relationships to disclose
Joseph A. Fontana
No relevant relationships to disclose
Daryn Smith
No relevant relationships to disclose
Elisabeth I. Heath
No relevant relationships to disclose
Karen Baranowski
No relevant relationships to disclose
Ulka N. Vaishampayan
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline